Colophon · The publisher
About This BPC-157 Research Console
An independent editorial project that reads the published BPC-157 literature like an instrument panel — and is explicit about what the "md" in the name does and does not mean.
What this project is
MD BPC-157 is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The console framing is the whole method. BPC-157's evidence base is mechanism-shaped and decision-shaped — one best-characterized angiogenic pathway, a measurable pharmacokinetic spine, a fan of per-kilogram rodent doses, and a stark human-data gap — and we render each as a readout rather than as prose persuasion. When the literature is precise, we report the figure and cite it. When it stops, we display the gap instead of filling it.
What the "md" in the name means
The "md" in MD BPC-157 is editorial framing, not a clinical claim. It marks the register this site reads in — the measured, instrument-panel voice of a research console that tracks who studies a compound, how its mechanism is mapped, and where compounded access stands. It is a position the publisher occupies relative to the literature, not a statement that this site is a medical practice, employs physicians, or offers any clinical service.
We say this plainly because the distinction matters. There is no doctor behind this console, no consultation, no prescription, no treatment. There is a cited reading of the published record — the mechanism on /mechanism, the studied findings on /research, the dose context on /dosage, and the regulatory status on /legal-status — and nothing on this site should be read as personalized medical guidance.
How we cite
Every quantitative claim on this site maps to a numbered citation in the reference register, and the references resolve to PubMed, DOIs, or — for the legal-status page — FDA.gov primary sources. We summarize what studies measured, in the species they measured it, at the doses they used; we do not recommend human doses, and we describe regulatory status as present-tense fact rather than forecast.
We also keep the human-data caveat visible rather than buried. As the 2025 reviews state, only three small human pilot studies of BPC-157 exist, and rigorous large-scale trials are lacking — so we present the deep preclinical record as exactly that, and we do not let it stand in for human efficacy. The reading is honest about its own limits, which is the point of reading it as a console at all.